ANL

Adlai Nortye (ANL)

About Adlai Nortye (ANL)

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Details

Daily high

$1.50

Daily low

$1.41

Price at open

$1.42

52 Week High

$2.99

52 Week Low

$0.88

Market cap

43.1M

Dividend yield

0.00%

Volume

14,268

Avg. volume

28,264

P/E ratio

Adlai Nortye News